Australia's #1 directory for medical equipment & suppliers

Bio-Rad Laboratories

Life Science Research Products & Clinical Diagnostics

Basic Profile
Follow
2 Followers
Bio-Rad Laboratories, Inc. (Amex: BIO; BIOb) is a multinational manufacturer and distributor of life science research products and clinical diagnostics.

Bio-Rad
Read more |Promo message
Promo message

Bio-Rad is based in Hercules, California, Bio-Rad serves more than 70,000 research and industry customers worldwide through a network of more than 30 wholly owned subsidiary offices.

Bio-Rad Laboratories announced financial results for the fourth quarter and fiscal year ended December 31, 2005. Net revenues from continuing operations were $307.3 million for the fourth quarter, essentially flat versus the prior-year quarter. On a currency- neutral basis, however, revenues were up 2.9% over the same period last year.

For the full year, Company sales from continuing operations grew by 8.3% to $1,181.0 million compared to $1,090.0 million in 2004. Normalizing for the impact of currency effects, growth was 7.3%. This growth was largely due to organic growth in Bio-Rad's two main business segments, Life Science ($549.9 million) and the Clinical Diagnostics ($618.4 million).

Hide promo message

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc. (Amex: BIO; BIOb) is a multinational manufacturer and distributor of life science research products and clinical diagnostics.

Bio-Rad supplies products worldwide to customers, including hospitals, universities, government agencies, biotechnology firms, and pharmaceutical companies. The company offers disease tests, as well as technological applications such as image analysis, molecular detection, chromatography, and gene transfer.

Promo message Bio-Rad Laboratories

Bio-Rad is based in Hercules, California, Bio-Rad serves more than 70,000 research and industry customers worldwide through a network of more than 30 wholly owned subsidiary offices.

Bio-Rad Laboratories announced financial results for the fourth quarter and fiscal year ended December 31, 2005. Net revenues from continuing operations were $307.3 million for the fourth quarter, essentially flat versus the prior-year quarter. On a currency- neutral basis, however, revenues were up 2.9% over the same period last year.

For the full year, Company sales from continuing operations grew by 8.3% to $1,181.0 million compared to $1,090.0 million in 2004. Normalizing for the impact of currency effects, growth was 7.3%. This growth was largely due to organic growth in Bio-Rad's two main business segments, Life Science ($549.9 million) and the Clinical Diagnostics ($618.4 million).